|
|
 |
 |
Depression Market Forecast
NEW YORK, March 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Depression Market Forecast product launches across the seven major markets will see the market expand incrementally to 2020, reinforcing the depression market's status as one of the largest of the CNS disorders.
R&D Trends: Depression - Clinical attrition driven by mature market conditions
NEW YORK, March 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
R&D Trends: Depression – Clinical attrition driven by mature market conditions
-–-Clinical-attrition-driven-by-mature-market-conditions.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Several drugs have progressed through the pipeline for depression in recent years, including Pristiq (desvenlafaxine; Pfizer), Oleptro (trazodone extended release; Labopharm), and Viibryd (Forest) in the US, and Valdoxan (agomelatine; Servier/Novartis) in the EU.
Rebecca Fierle Supports Mental Health Education for Senior Care Providers
ORLANDO, Fla., March 8, 2012 /PRNewswire/ -- According to the ConcordPatch, Caring Companion Home Care will be hosting a conference on senior depression. Hosted online, in conjunction with the National Private Duty Association, this conference will discuss the facts senior care providers need to know to properly address senior depression.
|